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Introduction
Evidence-based medicine (EBM) challenges cli-
nicians and laboratory professionals to make rational 
decisions in healthcare. The most common definition 
of EBM comes from Dr. David Sackett. EBM is »the 
conscientious, explicit and judicious use of current 
best evidence in making decisions about the care of 
the individual patient. It means integrating individual 
clinical expertise with the best available external clini-
cal evidence from systematic research« (1).
EBM is the integration of clinical expertise, pa-
tient values, and the best evidence into the decision 
making process for patient care. Clinical expertise 
refers to the clinician’s cumulated experience, educa-
tion and clinical skills. The patient brings to the en-
counter his or her own personal and unique concerns, 
expectations, and values. The best evidence is usually 
found in clinically relevant research that has been con-
ducted using sound methodology (2). The purpose of 
evidence-based medicine is to demonstrate and docu-
ment best medical practice on the basis of published 
studies and expert consensus. The »level of evidence« 
is graded on a scale from A to E, with A representing 
the highest level of evidence and E the lowest. EBM 
requires new skills of the clinician, including efficient 
literature-searching, and the application of formal 
rules of evidence in evaluating the clinical literature. 
The practice of evidence-based medicine is a process 
of lifelong, self-directed, problem-based learning in 
which caring for one’s own patients creates the need 
for clinically important information about diagnosis, 
prognosis, therapy and other clinical and health care 
issues (3). The practice of EBM involves the following 
steps:
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1.  construct a relevant, answerable question 
from a clinical case;
2.  plan and carry out a search for clinical litera-
ture;
3.  critically appraise the literature for validity 
and usefulness;
4.  apply the results of this appraisal to your 
clinical practice.
The practice of EBM advocates that clinicians 
search the published literature to find answers to their 
clinical questions. There are literally millions of pub-
lished reports, journal articles, correspondence and 
studies available to clinicians. Choosing the best re-
source to search is an important decision. A large da-
tabase such as MEDLINE gives access to the primary 
literature. Secondary resources such as ACP Journal 
Club, POEMS, Clinical Inquiries and Clinical Evidence 
provide assessment of the original study. The Co-
chrane Library provides access to systematic reviews 
which help summarize the results from a number of 
studies (3Ê5).
In this era of evidence-based medicine, clini-
cians and other decision-makers turn to the scientific 
literature for high-quality evidence about the useful-
ness, precision, and accuracy of diagnostic tests. 
Such evidence is needed more than ever because the 
list of diagnostic tests is growing exponentially, and 
even more biomarkers, proteomics, and applications 
of gene expression profiling will be added in the years 
to come (6). 
Evidence-Based Laboratory Medicine 
Some of the barriers for the laboratory medicine 
community are not significantly different from those 
faced by physicians trying to adapt to an evidence-
based world. Many clinical and laboratory profes-
sionals in all disciplines have felt uncomfortable with 
evidence-based practice and with the challenge of 
the clinical consultant role. This has not been made 
easier by laboratory reorganization, which has often 
promoted an industrial rather than a clinical model 
for laboratory medicine. There is little doubt that the 
way laboratory data are presented to clinicians is not 
user-friendly and does not help them with decision 
making (7).
»Evidence-based laboratory medicine (EBLM) 
integrates into clinical decision making the best avail-
able research evidence for the use of laboratory tests 
with the analytical and clinical expertise and experi-
ence of health care professionals and the needs and 
expectations of patients« (8). Practicing EBLM has 
four dimensions: (a) identification of the question; 
(b) critical assessment of the best evidence available, 
embodying the principles of health technology as-
sessment; (c) implementation of best practice; and 
(d) maintaining best practice; the latter embodies the 
principles of clinical audit (9). The travails of evidence-
-based laboratory medicine are similar to those faced 
by clinicians. Preanalytical, analytical, postanalyti-
cal, and other technical or organizational elements 
of diagnostic performance should be seen as part of 
evidence-based laboratory medicine. We might not 
always be able to identify in quantitative terms the 
impact of all elements of test performance on clinical 
outcomes in laboratory medicine. The need to im-
prove the quality and reporting of randomized control 
trials led to the Consolidated Standards of Reporting 
Trials (CONSORT) statement (10, 11), and it is hoped 
that the Standards for Reporting of Diagnostic Accu-
racy (STARD) statement will lead to a complete and 
accurate reporting of studies on diagnostic accuracy 
(12, 13). 
Evidence-based guidelines in laboratory 
medicine
Guidelines are commonly used tools for sup-
porting medical decisions. Formulating evidence-
-based recommendations has become a leading 
principle in guideline development. Guidelines should 
be developed in a transparent process by a multidis-
ciplinary team, with graded recommendations based 
on critically appraised scientific studies. Systematic, 
standardized, and explicit methodology, adapted to 
laboratory medicine, should be followed when deve-
loping recommendations involving the use of labo-
ratory tests. Guidelines combine scientific evidence 
with patients’ choices, clinicians’ experience, and the 
availability of resources (14, 15).
In laboratory medicine, guidelines provide re-
commendations on the use of a wide range of tests in 
detecting or predicting a target condition, for staging 
and monitoring a disease, and for decisions to initiate, 
modify, or terminate treatments (13). Also, high-level 
diagnostic evidence is particularly scarce, and the link 
between diagnostic tests and better patient outcomes 
is often unknown (16). Evidence-based guideline 
de ve  lopment is a hard, time-consuming, and costly 
exercise. Producing high-quality, scientifically sound, 
practical, clinically and socially acceptable, and con-
tinuously updated recommendations requires special 
skills and standardized procedures. High-quality guide-
lines are based on evidence as well as a broad con-
sensus of opinions, which facilitates the acceptance 
and effective use of the guideline in the target group 
(17). To ensure high quality, guidelines should be de-
veloped within a structured and coordinated program 
according to the principles of evidence-based guide-
line development (18).
The AGREE (Appraisal of Guidelines Research 
and Evaluation) Instrument is a tool for assessing the 
quality of clinical guidelines according to 23 criteria, 
grouped into 6 domains (scope and purpose, stake- 
-holder involvement, methodology, clarity and presen-
tation, applicability, and editorial independence). The 
Instrument is available in more than 10 languages and 
is currently used in many countries around the world. 
The AGREE criteria mainly concern the methods used 
Jugoslov Med Biohem 2006; 25 (3) 229
for developing the guideline and the quality of report-
ing (19, 20). Watine et al (21) report the results of their 
test of the correlation between guideline quality and 
clinical validity of recommendations for 11 guidelines 
on a specific topic (non-small cell lung cancer) in labo-
ratory medicine. Guideline quality was measured with 
the AGREE Instrument summarized in a global score. 
This study is the first to test the relationship between 
the AGREE quality scores and the clinical content of 
guidelines, a process that could be considered as a 
next step in validating the AGREE Instrument. The re-
sults revealed that there was no relationship: »good« 
as well as »not so good« guidelines contained »good« 
recommendations, corresponding with the evidence 
of the systematic review, and even »good« guidelines 
included »not so good« recommendations. These 
findings confirm the variability of the translation of 
evidence into practice recommendations by different 
guideline groups. Further validation of the AGREE 
Instrument would be the next step in achieving more 
international consensus about guideline quality and 
methodology (18, 22).
For many reasons, the methodologic quali ty 
of diagnostic guidelines is poorer than that of thera-
peutic guidelines, particularly in the field of labora-
tory medicine (14, 21, 22). Laboratory professionals 
should be involved in guideline development if labora-
tory tests are included in clinical recommendations. 
On the other hand, guidelines developed exclusively 
by laboratory professionals are equally of limited 
value in terms of both recognition and implementa-
tion. They can, however, serve as a position statement 
of the discipline and as a starting point for further (or 
local) multidisciplinary development of clinical guide-
lines. Because of the size and complexity of the task, 
guideline development is best coordinated by national 
or international organizations specialized in the field 
(14).
Biomarkers of diseases: 
an evidence-based approach
Laboratory medicine also provides some of the 
more overt examples of practice lacking a good foun-
dation of evidence, the best examples perhaps being 
the variations seen in testing strategies between dif-
ferent hospitals for the same clinical presentations. 
Systematic, standardized, and explicit methodology, 
adapted to laboratory medicine, should be followed 
when developing recommendations involving the use 
of laboratory tests and biomarkers.
There are many opportunities for the applica-
tion and evaluation of laboratory tests in good clinical 
trials. There are even greater opportunities for corre-
lating various laboratory procedures with the clinical 
findings, outcomes and diagnoses, and using the 
stored samples collected for those studies. Choles-
terol was earlier used as an example of a laboratory 
test, with its clinical use having been clearly estab-
lished by many large clinical trials. There have been 
many large and expensive clinical outcome studies 
that have looked at major endpoints such as myocar-
dial infarction, mortality, and complication rates (25). 
Laboratory testing cannot attract funding for similar 
studies. However, there is an opportunity for much 
greater involvement in these clinical trials (7). 
Another example is C-reactive protein, which 
has very low diagnostic specificity, but has long 
been used as an acute-phase marker of injury, infec-
tion, and inflammation and may also indicate future 
cardiovascular disease (26). Recent evidence has 
shown that inflammation plays a pivotal role in the 
inception and progression of atherosclerosis, and 
population studies have demonstrated a strong and 
independent association between baseline concentra-
tions of inflammatory biomarkers and future coronary 
events (27Ê30). Because the majority of individuals 
who develop coronary events are not in a high-risk 
group according to the Framingham risk assessment 
of traditional risk factors for coronary heart disease, 
and because one half of those who suffer myocardial 
infarctions have normal lipid values, measurement 
of inflammatory markers has been suggested as an 
adjunct to lipid testing to better identify individuals at 
increased risk (31). Of the inflammatory markers eval-
uated by the CDC and American Heart Association 
(AHA) Panel in 2002 (32, 33), only C-reactive protein 
(CRP) met the analytical requirements for outpatient 
clinical use and, therefore, has been studied intensely 
over the past decade. More than 25 prospective epi-
demiologic studies have shown that CRP is a strong 
and independent predictor of future myocardial in-
farction, ischemic stroke, peripheral arterial disease, 
and sudden cardiac death in apparently healthy men 
and women (34). Guidelines regarding the potential 
usefulness of CRP in primary and se condary preven-
tion settings have been issued by the CDC and AHA 
(32). To assess CHD risk, CRP must be measured by 
highly sensitive methods (hsCRP) that are capable of 
reliably measuring concentrations within the healthy 
reference interval. Currently, more than 30 such 
methods are available world-wide, many of which 
have been cleared by the US Food and Drug Admini-
stration (FDA). The FDA issued new guidelines for 
industry and FDA staff regarding this analyte, enti-
tled Review Criteria for Assessment of C-Reactive 
Protein (CRP), High Sensitivity C-Reactive Protein 
(hsCRP) and Cardiac C-Reactive Protein (cCRP) 
As says (35).
An accurate, noninvasive, and efficient method 
of detecting substantial coronary artery disease in 
otherwise apparently low-risk patients remains an 
unmet need. In the emergency department setting, 
the subpopulations of patients who represent the 
greatest challenge in decision making are these low-
risk patients. Published literature was systematically 
reviewed to determine the diagnostic accuracy of new 
protein markers of acute coronary syndromes (ACS) 
in symptomatic outpatients at low risk of ACS and re-
lated complications comparable to patients evaluated 
230  Ignjatovi}: Biomarkers of disease: an evidence-based approach
in emergency department chest pain units. Published 
evidence is not sufficient to support the routine use 
of new protein markers in screening for ACS in the 
emergency department setting (36).
The newly revised definition of acute myocar-
dial infarction (AMI) required specific clinical and/or 
electrocardiographic findings to be coupled with in-
creased blood concentrations of myocardial troponin 
(released into the circulation after myocardial cell 
death). Troponin (I or T) is the favored biomarker for 
myocardial necrosis because it is both highly sensi-
tive and specific (37, 38). Furthermore, the document 
confirmed that a normal electrocardiogram (ECG) 
does not rule out myocardial infarction because the 
new, sensitive biomarkers detect very small amounts 
of myocardial necrosis in a range where ECG abnor-
malities may not develop. According to the consensus 
document of 2000, myocardial infarction would be 
diagnosed if an appropriately timed blood sample 
contained a troponin concentration that exceeded 
that at the 99th percentile of a reference population, 
or contained a troponin concentration that exceeded 
the concentration at which the assay achieved a 
10% CV if that concentration was higher than the 
concentration at the 99th percentile. The consensus 
document specified that the interval between suc-
cessive troponin samples should be 6 h. MacRae et 
al (39) determined that an interval as short as 3 h 
between troponin samples yielded the same accuracy 
in defi ning an acute myocardial infarction as the 6-h 
samples used previously. However, this conclusion 
applied only when the reference sample was taken at 
least 6 h after the onset of THE symptoms of myocar-
dial infarction (39). The results of the data presented 
by MacRae et al (39) will be of considerable interest to 
clinicians seeking urgent or emergent revasculariza-
tion of ischemic myocardium. The results of their trial 
could enable clinicians to identify an acute myocar-
dial infarction earlier than had been thought to be the 
case in the past (39).
It is also recognized that clinicians will be faced 
with the determination of D-dimer as a laboratory 
test that is said to detect venous pulmonary embo-
lism, and the measurement of D-dimer has been stu-
died extensively as an adjuvant test in the diagnosis 
of deep venous thrombosis (DVT). The turbidimetric 
D-dimer test is sensitive but nonspecific for the de-
tection of pulmonary embolism in the emergency 
department setting, and D-dimer tests using latex 
turbidimetric methods appear to have test characte-
ristics comparable to those for ELISA methods (40). 
On the other hand, the use of D-dimer assays as a 
rule-out test for DVT is controversial. If the sensitivity 
of the D-dimer test for DVT is consistently very high, 
its negative predictive value will also be high and reli-
ably exclude the presence of disease. These are cha-
racteristics of a good »rule-out« test. As such, the use 
of the D-dimer assay has been suggested as an initial 
test to rule out DVT in order to reduce the number of 
patients requiring diagnostic imaging. Heim et al re-
viewed 23 studies on the use of D-dimer assays in the 
diagnosis of lower extremity DVT. Their review of the 
accuracy of the literature does not support general 
use of the D-dimer assay as a stand-alone rule-out 
test for DVT. We found wide variation in the sensitivi-
ties of D-dimer assays for diagnosing DVT and even 
wider variation in specificities. Test characteristics 
were frequently inconsistent with those of a good 
rule-out test (41).
One study (21) assessed to what extent metho do-
logic quality is linked to recommendation validity in 
practice guidelines for the use of laboratory tests in 
the management of patients with non-small cell lung 
cancer (NSCLC), specifically laboratory tests measur-
ing quantities in biological specimens, thus excluding 
tissue (or anatomic) pathology tests. They conducted 
a systematic review of data on laboratory tests in 
NSCLC published in English or in French within the 
last 10 years and retrieved 11 practice guidelines for 
the use of these tests. The guidelines were critically 
appraised and scored for methodologic quality and 
recommendation validity based on the AGREE criteria 
and the systematic review. Overall, these 11 guide-
lines had considerable shortcomings in methodo logic 
qua lity and, to a lesser extent, in recommendation va-
lidity. Practice guidelines with the best methodologic 
qua lity were not necessarily the most valid in their 
recommendations, and conversely. Poor methodo-
logic quality and lack of recommendation validity in 
laboratory medicine call for methodologic standards 
of guideline development and for international colla bo-
ration of guideline development agencies. They advise 
readers of guidelines to critically evaluate the methods 
used, as well as the content of the recommendations, 
before adopting them for use in practice.
The incidence of acute and chronic heart failure 
has increased substantially during recent decades 
because of aging populations in the Western world, 
arising, at least partially, from medical progress with 
extended life expectancies. The diagnosis and prog-
nostic evaluation of heart failure are still challenging 
problems in clinical medicine because simple and 
accurate diagnostic techniques are not available. In 
daily routine, diagnosis of heart failure is based mainly 
on the patient’s history and clinical findings and, oc-
casionally, on the echocardiographic evaluation of the 
left ventricular (systolic) function and dimensions. 
Natriuretic peptides are promising markers in diag-
nosing acute and chronic heart failure and assessing 
prognosis in these patients. Increasing routine use 
for unselected patients is challenged by false-positive 
results. Most recently, it has been confirmed that NT-
proBNP is a promising marker for the identification of 
patients with structural heart disease in the emergen-
cy room and a suitable tool for risk stratification, but 
its use for the emergency room should at present be 
limited to clearly clinically defined patient groups to 
avoid a potential excess of additional diagnostic pro-
cedures in positive but asymptomatic patients (42).
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The landscape of prostate cancer has changed 
since the appearance of the first prostate-specific an-
tigen (PSA) assay. Key elements in PSA measurement 
are the interchangeability of assays and the stability 
of serum samples before tests (43, 44). Following the 
critical appraisal of the available information, criteria 
have been proposed to help physicians use the infor-
mation from published studies to estimate the real 
usefulness of total and free prostate-specific antigens 
(tPSA and fPSA) in clinical decisions about prostate 
carcinoma. Different assays for the concentrations of 
tPSA and fPSA provide discordant results (45). These 
assay-dependent variations could lead to the misin-
terpretation of individual PSA values and erroneous 
clinical decisions about prostate carcinoma. Stephan 
et al (46) showed that the interchangeability of meth-
ods is a problem for clinical samples. In that study, 
they took great care when storing samples and per-
forming the assay, and the reliability of the measured 
values was high. The percentage free PSA (%fPSA) is 
related to both total PSA and free PSA and needs to 
be evaluated carefully. As Stephan et al indicated, for 
patients in whom the %fPSA determines whether a 
prostate bi opsy is performed, the result might depend 
on the assay used. Thus it seems important that total 
and free PSA be measured by compatible methods. 
Interchangeability of tPSA, fPSA, and %fPSA values 
obtained by commercial PSA assays remains inad-
equate, but attention to this issue may minimize the 
misinterpretation of PSA results obtained by different 
assays (46).
There are also evidence-based studies for the 
performance characteristics of urinary bone markers 
for monitoring the treatment of osteoporosis, because 
the usefulness of urinary markers of bone turnover in 
monitoring therapy depends on their within-person 
variability (47Ê49). All of these studies link laboratory 
and clinical medicine through analysis that is data- 
-driven and critically evaluated. 
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Kratak sadr`aj: Medicina zasnovana na dokazima (EBM) pri dono{enju odluka o nezi pacijenata kombinuje 
individualnu klini~ku ve{tinu sa najboljim raspolo`ivim klini~kim dokazima iz sistemati~nih istra`ivanja. 
Klini~ka ve{tina odlikuje se ta~no{}u u proceni i sti~e se u~enjem, klini~kim iskustvom i praksom. Klini~ki 
dokazi dobijaju se iz klini~kih istra`ivanja koja su usmerena na pacijenta, a koja ispituju ta~nost i preciznost 
dijagnosti~kih testova i biomarkera, efikasnost i sigurnost terapeutskih postupaka i pouzdanost prognosti~kih 
indikatora. Kombinacija klini~ke ve{tine i dokumentovanih dokaza omogu}ava sigurniju, efikasniju i pouz daniju 
negu pacijenta. Vodi~i zasnovani na dokazima naj~e{}e se koriste kao dodatne alatke pri dono{enju medicinskih 
odluka. Formulisanje preporuka zasnovanih na dokazima predstavlja vode}i princip u pripremi vodi~i. U razvoju 
preporuka koje uklju~uju laboratorijske testove i biomarkere treba primeniti sistematsku i standardizovanu 
metodologiju koja je prilago|ena laboratorijskoj medicini. Postoji veliki broj mogu}nosti za primenu i evaluaciju 
laboratorijskih testova u dobrim klini~kim ispitivanjima. Jo{ su ve}e mogu}nosti za uspostavljanje korelacija 
izme|u razli~itih laboratorijskih postupaka i klini~kih nalaza, ishoda i dijagnoza, kao i za kori{}enje uzoraka 
koji su skladi{teni za ova ispitivanja. Era medicine zasnovane na dokazima zahteva od eksperata koji donose 
medicinske odluke prou~avanje nau~ne literature kako bi se obezbedio visok kvalitet dokaza o korisnosti i 
ta~nosti dijagnosti~kih testova. Ovakva vrsta dokaza potrebnija je vi{e nego ikad zato {to lista dijagnosti~kih 
testova raste eksponencijalno i u godinama koje dolaze na nju }e biti dodato jo{ vi{e biomarkera, proteomike 
i aplikacija profiliranja ekspresije gena.
Klju~ne re~i: medicina zasnovana na dokazima, laboratorijska medicina zasnovana na dokazima, 
biomarkeri, laboratorijska vodi~i zasnovana na dokazima
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